Application of massively parallel methods identified one third of the complete proteome, a majority of which was only predicted based on genome sequencing, but never identified to date.
Regarding the 52 INDELs identified, one third (17) could be classified as mono-, di-, tri- and tetranucleotide variants whereas the two other thirds (35) represented variable size INDELs ranging from one to 38 bp.
Thus, it failed to identify one-third of the anchor domains and assigned the others in a shortened form, omitting part of the coiled-coil that forms the N-terminal third of this domain.
Broadening the testing strategy to include those children with deep breathing and jaundice in addition to those children with altered consciousness would still have failed to identify one-third of children with hypoglycemia.
Analyses of data from the National Health and Nutrition Examination Survey (NHANES) indicate that the HbA1c threshold of ≥6.5% identifies one-third fewer cases of undiagnosed diabetes than a fasting glucose cut-off point of ≥7.0 mmol/l [10], which results in differences in study populations depending on the diagnosing tests.
A1C ≥6.5% identifies one-third of patients with diabetes.
This is in agreement with a neonatal VA study from the same setting, which identified one-third of asphyxia deaths as being associated with obstetric complications.
Analyses of NHANES data indicate that, assuming universal screening of the undiagnosed, the A1C cut point of ≥6.5% identifies one-third fewer cases of undiagnosed diabetes than a fasting glucose cut point of ≥126 mg/dl (7.0 mmol/l) (www.cdc.gov/diabetes/pubs/factsheet11/tables1_2.htm).
Analyses of National Health and Nutrition Examination Survey NHANESS) data indicate that, assuming universal screening of the undiagnosed, the A1C cut point of ≥6.5% identifies one-third fewer cases of undiagnosed diabetes than a fasting glucose cut point of ≥126 mg/dl (7.0 mmol/l) (7).
By ELISA, IB, ID, or IP, a total of 159 anti-Ku-positive patients were identified: one-third had an overlap syndrome, 28% SLE, 4% dermatomyositis/-polymyositis (DM/PM), 14% SSc, and 20% other autoimmune diseases.
